The world faces a growing tuberculosis crisis, with an estimated 10.8 million people falling ill in 2023. This marks a 0.9% increase from 2022 and represents the highest number of newly diagnosed cases since global monitoring began in 1995. Despite rising infections, improved detection methods and powerful advocacy from survivors are driving critical changes in the global response.[paho+4]
TB Surpasses COVID-19 as Leading Infectious Killer
Tuberculosis has once again surpassed COVID-19 as the world's leading infectious disease killer. In 2023, approximately 8.2 million people were newly diagnosed with TB, a notable increase from 7.5 million reported in 2022. This surge reflects a 4.6% rise in the TB incidence rate between 2020 and 2023, reversing previous declines seen from 2010 to 2020.[paho+3]
While the number of TB-related deaths decreased slightly to 1.25 million in 2023 from 1.32 million in 2022, this figure still vastly exceeds the 320,000 COVID-19 deaths officially reported to the World Health Organization (WHO) last year. The disease disproportionately affects certain populations, with 55% of those who developed TB in 2023 being men, 33% women, and 12% children and young adolescents.[cidrap+3]
The global burden of TB is heavily concentrated in 30 high-burden countries, which account for 87% of all cases. Five nations—India, Indonesia, China, the Philippines, and Pakistan—alone contributed to 56% of the global total in 2023.
Faster, Smarter TB Detection Methods Emerge
Amid the rising case numbers, there is positive news regarding TB detection. The gap between the estimated number of people who fall ill with TB and those who are officially diagnosed narrowed to about 2.7 million in 2023. This is a significant improvement from the approximately 4 million undetected cases during the peak of the COVID-19 pandemic in 2020 and 2021, indicating a recovery in TB services.
Recent years have seen substantial advancements in diagnostic tools. Rapid molecular tests, such as the Xpert MTB/RIF and Truenat assays, are now recommended by the WHO for initial diagnosis. These tests can quickly detect both TB and resistance to rifampicin, a key anti-TB drug. Their use has been increasing, though access remains a challenge in many low- and middle-income countries due to cost.[paho+3]
New technologies are also expanding diagnostic capabilities beyond traditional sputum tests. Innovations include liquid culture and line probe assays for faster drug susceptibility testing. A new fingerstick blood-based test, Xpert MTB Host Response (MTB-HR), is under development, aiming to provide a rapid, non-sputum option. Urine-based antigen tests, like the Determine TB LAM Ag test, are proving particularly useful for diagnosing TB in people living with HIV.[pmc+2]
Artificial intelligence and machine learning are also beginning to play a role, with AI/ML-based systems being developed to automate the interpretation of sputum smears, which could reduce manual errors and improve efficiency. These technological leaps are crucial for early diagnosis, which is vital for effective treatment and preventing further spread.[pmc+2]
Survivors Drive Change and Fight Stigma
Tuberculosis survivors are increasingly stepping forward to share their stories, becoming powerful advocates for change in the global fight against the disease. These personal narratives highlight the devastating impact of TB, including the severe stigma and mental health challenges that often accompany a diagnosis.
Fatima Karmadwala, an MDR-TB survivor from the UK, shared her experience of being diagnosed in 2017 while at university. She recounted facing significant stigma, even from hospital staff, and feeling isolated. "I spent 50 days in one room. My lunch was left on a bin in the hallway outside of my room, because staff members refused to wear a mask and come in," Karmadwala told an audience at a parliamentary reception. Her advocacy now aims to combat this stigma and ensure better treatment for patients.[respiratoryfutures+3]
Similarly, Bi Hawa Mohammed, a TB survivor and community health champion in Tanzania, experienced the profound economic and social fallout of the disease. Her sardine business closed during her illness, underscoring how TB can derail livelihoods. With support from Amref Health Africa, Bi Hawa not only recovered but also became an advocate, working with women's groups to promote early testing and treatment and fight stigma in her community.[results]
These survivor voices are critical in influencing policymakers and health organizations. They emphasize the need for person-centered care, gender- and rights-responsive treatment approaches, and increased funding for TB research and prevention. Advocates regularly meet with leaders to stress that TB is a public health priority requiring more resources for diagnostics, drugs, and vaccines.[amrefcanada]
The commitment of survivors is inspiring renewed efforts to tackle drug-resistant TB, which remains a public health crisis. In 2023, an estimated 400,000 people developed multidrug- or rifampicin-resistant TB. While only 44% of these cases were diagnosed and treated, the treatment success rate for MDR/RR-TB has reached 68%. Newer, shorter treatment regimens, such as BPaLM and BDLLfxC, are being scaled up, with 34,000 people starting them in 2024, a substantial increase from previous years.[respiratoryfutures+2]
Global efforts have saved an estimated 79 million lives since 2000. However, the rising case numbers underscore that the fight against TB is far from over. Continued investment in advanced diagnostics, accessible treatment, and robust community-led initiatives, powered by the courage of survivors, remains essential to achieve the goal of ending the global TB epidemic.[paho+5]
